Clinical trials: Hepatitis B, completed
Hepatitis B
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Dose escalation or repetition will be governed by pre-specified safety and activity rules.
- Trial name
- NCT01590654
- Testing
- Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts GS-9620
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 51 people
- Sponsor
- Gilead Sciences
Hepatitis B, Haemophilus Influenzae Type b Immunisation
Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea
Primary objectives: To investigate the incidence of adverse events occurred following administration of Hexaxim in infants from 2 months of age under routine clinical practice, as per approved indications
- Trial name
- NCT06793826
- Testing
- DTaP-IPV-Hep B-PRP-T combined vaccine
- Where
- 2 sites in South Korea
- Volunteers
- 713 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
HIV Infections
Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs
The purpose of this study is to determine immune system function following vaccination in HIV-infected children currently taking anti-HIV drugs.
- Trial name
- NCT00257127
- Testing
- Pneumococcal 7-valent conjugate vaccine, Pneumococcal polysaccharide vaccine, Hepatitis B vaccine
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 101 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B
PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant Patients
Open-label pharmacokinetic drug interaction study.
- Trial name
- NCT00644761
- Testing
- Adefovir Dipivoxil
- Where
- 11 sites in United States
- Volunteers
- 16 people
- Sponsor
- Gilead Sciences
Hepatitis B, Chronic
Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B
Compare the safety of four oral doses of pradefovir after 48 weeks of treatment Select the dose of pradefovir for Phase 3 studies
- Trial name
- NCT00230503
- Testing
- pradefovir mesylate, adefovir dipivoxyl
- Volunteers
- 220 people
- Sponsor
- Bausch Health Americas, Inc.
Hepatitis, Viral, Human, Blood Transfusion
Natural History of Post-transfusion Non-A, Non-B Hepatitis
To compare the clinical, biochemical, and histological status of Non-A, Non-B post-transfusion hepatitis patients with that of patients who did not develop post-transfusion hepatitis.
- Conditions
- Hepatitis, Viral, Human, Blood Transfusion, Liver Diseases
- Trial name
- NCT00005306
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hepatitis B, Chronic
Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA
This is a randomized, open-labelled, prospective 96-week study comparing the antiviral efficacy and safety of switching to entecavir 0.5mg QD from lamivudine versus maintaining lamivudine 100mg QD treatment in CHB patients…
- Trial name
- NCT00637663
- Testing
- Entecavir, Lamivudine
- Where
- 2 sites in South Korea
- Volunteers
- 72 people
- Sponsor
- Pusan National University Hospital
HBV (Hepatitis B Virus), Hepatitis B
Lamivudine and Adefovir to Treat Chronic Hepatitis B
This study will evaluate the safety and effectiveness of lamivudine plus adefovir versus adefovir alone to treat chronic hepatitis B infection.
- Conditions
- HBV (Hepatitis B Virus), Hepatitis B, Hepatitis
- Trial name
- NCT00023309
- Testing
- Lamivudine and adefovir, Adefovir alone
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis B, Polio
Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule
To demonstrate that the immune response to hepatitis B antigen of the DTaP-IPV-Hep B-PRP~T is non-inferior to that of the association of PENTAXIM™ and ENGERIX B® one month after a three dose (2-3-4 month) primary series.
- Conditions
- Hepatitis B, Polio, Diphtheria, Pertussis
- Trial name
- NCT00315055
- Testing
- DTaP-IPV-HB-PRP~T vaccine, DTaP-IPV//PRP~T combined, Hepatitis B vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hepatitis B
Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection
The purpose of this study is to compare the efficacy and safety of 48-week treatment with Clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection.
- Trial name
- NCT00362635
- Testing
- Clevudine
- Where
- 2 sites in Hong Kong
- Volunteers
- 92 people
- Sponsor
- Bukwang Pharmaceutical
Chronic Hepatitis B
Safety Study of HBV DNA Vaccine to Treat Patients With Chronic Hepatitis B Infection
The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing.
- Trial name
- NCT00277576
- Testing
- ppdpSC18 administered by PMED
- Where
- 9 sites in Hong Kong, Singapore and 2 more
- Volunteers
- 48 people
- Sponsor
- PowderMed
Hepatitis B
Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects
The primary objective is to evaluate the safety and tolerability of single oral doses of NCO-48 Fumarate in healthy subjects. The secondary objectives are to evaluate the pharmacokinetic (PK) profile of NCO-48 Fumarate and its…
- Trial name
- NCT04309526
- Testing
- NCO-48 Fumarate
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Nucorion Pharmaceuticals, Inc.
Hepatitis B
Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine at Different Viral Concentrations in Healthy Infants
To assess the efficacy, immune response and safety of 2 doses of HRV vaccine (at different concentrations) in healthy infants aged approximately 3 months previously uninfected with human rotavirus.
- Trial name
- NCT00429481
- Testing
- Rotarix
- Volunteers
- 2,464 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine
The purpose of the study is to evaluate the safety and immunogenicity of an investigational hepatitis B vaccine (HEPLISAV) in adults 18 to 70 years of age.
- Trial name
- NCT02117934
- Testing
- HEPLISAV, Engerix-B
- Where
- 40 sites in United States
- Volunteers
- 8,374 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
Hepatitis B
A Study to Evaluate Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of Engerix™-B Kinder Challenge Dose, in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa During Infancy
The purpose of this study is to assess the long-term persistence of immunity to hepatitis B in adolescents aged 14-15 years who were vaccinated with four doses of Infanrix™-Hexa in the first two years of life and to assess the…
- Trial name
- NCT02798952
- Testing
- Engerix-B Kinder
- Where
- 14 sites in Germany
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B Infection
A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054)
A study to evaluate the safety, tolerability, and immunogenicity of a recombinant hepatitis B vaccine manufactured using an upgrade to the production process.
- Trial name
- NCT00489099
- Testing
- V232 Modified Process Hepatitis B Vaccine: Lot A, V232 Modified Process Hepatitis B Vaccine: Lot B, V232 Modified Process Hepatitis B Vaccine: Lot C
- Volunteers
- 860 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HBV, Chronic HBV Infection
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)
The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis…
- Trial name
- NCT02836249
- Testing
- TAF, TDF
- Where
- 25 sites in China
- Volunteers
- 181 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant
The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF)-containing regimens at Week 24 in participants with chronic…
- Trial name
- NCT02862548
- Testing
- TAF, TDF, Other approved antivirals
- Where
- New Zealand
- Volunteers
- 51 people
- Sponsor
- Gilead Sciences
Entecavir for Chronic Hepatitis B Patients
Entecavir for Chronic Hepatitis B
The primary aim of this study is to asses the efficacy (both virological and clinical) and safety of ETV in both NA-naïve and NA-experienced chronic hepatitis B patients, and to explore baseline factors associated with virologic…
- Trial name
- NCT01323452
- Testing
- Entecavir
- Where
- Netherlands
- Volunteers
- 418 people
- Sponsor
- Foundation for Liver Research
Chronic Hepatitis B
Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in Chronic Hepatitis B Patients
The aim is to investigate the best treatment regime of PEG-Intron A and lamivudine combination in terms of viral clearance in chronic hepatitis B patients.
- Trial name
- NCT00226447
- Testing
- Pegylated Interferon, Lamivudine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese University of Hong Kong
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.